Different modes of maintenance iron supplementation in dialysis patients with renal anemia:a clinical study

Objective To compare the efficacy and safety of different modes of maintenance iron supplementation in dialysis patients whose renal anemia were combated, in order to find a better strategy of maintenance iron supplementation. Methods Forty hemodialysis patients whose renal anemia were combated in our Hemodialysis Center from September 2014 to March 2016 were divided into two groups randomly and treated with intravenous iron sucrose and oral polysaccharide iron complex respectively. Intravenous iron sucrose group (intravenous group) was given intravenous iron sucrose (100 mg, once a weak), and oral medication group (oral group) received poly saccharide iron complex (150 mg, once daily for 12 weeks). The count of red blood cells (RBC), Hb, Hct, SF, TSAT and CRP were examined before and 12 weeks after treatment. Results The Hb, RBC, SF, TSAT and Hct between the two groups had no significant difference before and after treatment (P>0.05). As compared with those before treatment, the levels of Hb, RBC, SF of all patients at 12th week were reduced, especially in the oral group. No adverse event was found in intravenous group. Conclusions Maintenance iron supplementation is essential for dialysis patients even though their renal anemia was mended. Both of intravenous iron sucrose and oral polysaccharide iron complex associated with EPO could be chosen to stabilize the parameters about iron and the level of Hb, but the mode of intravenous iron sucrose is safer and more efficacious, and easier to carry out.